Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.69 |
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.80 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.80 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.80 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436748 | 0.99 | GUCY1B2 (0.81) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL18899404 | 0.89 | GUCY1B2 (0.65) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| Hydrochloric Acid SCHEMBL253278 | 0.89 | GUCY1B2 (0.85) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL29778216 | 0.89 | GUCY1B2 (1.00) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3439299 | 0.89 | GUCY1B2 (1.00) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| Hydrochloric Acid SCHEMBL10321665 | 0.88 | GUCY1B2 (0.81) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3436772 | 0.88 | GUCY1B2 (0.84) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3436901 | 0.88 | GUCY1B2 (0.75) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3437556 | 0.88 | GUCY1B2 (0.75) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3436905 | 0.88 | GUCY1B2 (0.87) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-10844064-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| CN-107021951-B | sGC stimulators | 赛克里翁治疗有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-20190345130-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10189809-B2 | SGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180155345-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20170305878-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3194386-A2 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3173407-A1 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2588465-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-3112363-A1 | 2-[1-[(2-FLUOROPHENYL)METHYL]-5-(3-ISOXAZOLYL)-1H-PYRAZOL-3-YL]-PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | Ironwood Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2797915-B1 | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure | IRONWOOD PHARMACEUTICALS INC (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016044446-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150342954-A1 | 2-BENZYL, 3-(PYRIMIDIN-2-YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-9139564-B2 | 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2797915-A1 | 2 - BENZYL, 3 - (PYRIMIDIN- 2 -YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8748442-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| WO-2013101830-A1 | 2 - BENZYL, 3 - (PYRIMIDIN- 2 -YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20120184516-A1 | sGC Stimulators | CYCLERION THERAPEUTICS, INC. | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184516-A1 | sGC Stimulators | GUCY1A1, PTGIS, GUCY1B1 | OPRK1 598/4885GUCY1B2 6/4885GUCY1A2 4/4885 |
| US-20170305878-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | OPRK1 598/4885GUCY1B2 6/4885GUCY1A2 4/4885 |
| US-20150342954-A1 | 2-BENZYL, 3-(PYRIMIDIN-2-YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS | PTGIS, PDE3B, GMPS | OPRK1 595/4885GUCY1B2 9/4885GUCY1A2 4/4885 |
| US-10189809-B2 | SGC stimulators | GUCY1A1, PTGIS, GUCY1B1 | OPRK1 598/4885GUCY1B2 6/4885GUCY1A2 4/4885 |
| US-10844064-B2 | sGC stimulators | GUCY1B1, GUCY1A1, PRKG1 | OPRK1 381/4885GUCY1B2 4/4885GUCY1A2 6/4885 |
| US-20190345130-A1 | SGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | OPRK1 598/4885GUCY1B2 6/4885GUCY1A2 4/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | OPRK1 598/4885GUCY1B2 6/4885GUCY1A2 4/4885 |
| US-20180155345-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, PRKG1 | OPRK1 381/4885GUCY1B2 4/4885GUCY1A2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.